Astana – Kazakhstan is experiencing a significant rise in Alzheimer’s disease diagnoses, mirroring a global trend driven by demographic shifts and, crucially, improved detection methods. While the numbers are concerning, experts emphasize that the increase isn’t necessarily due to a surge in new cases, but rather a greater awareness and ability to identify the condition – a pattern seen across the globe as healthcare systems mature. However, the lack of dedicated national programs and economic assessments paints a concerning picture of preparedness for a rapidly aging population.
- Rising Incidence: Registered Alzheimer’s cases in Kazakhstan increased over 700% between 2021 and 2025, though experts attribute much of this to better detection.
- Global Projections: Worldwide, dementia cases are projected to reach 78 million by 2030 and 139 million by 2050, with the most significant increases expected in developing nations.
- Treatment Gap: While some symptomatic treatments are available, cutting-edge therapies slowing disease progression – approved in the US, Europe, and parts of Asia – are not yet accessible to Kazakh patients.
The increase in reported cases – from 496 in 2021 to 3,706 in 2025 – is a clear indicator that Kazakhstan is facing the challenges of an aging population. This demographic shift is not unique to Kazakhstan; globally, life expectancy is increasing, leading to a larger proportion of individuals at risk for age-related cognitive decline. However, the significant jump in diagnoses also highlights a positive development: increased awareness among medical professionals and a more systematic approach to identifying cognitive impairment. As psychotherapist Zhibek Zholdasova notes, the perception that Alzheimer’s is becoming younger is largely a result of improved diagnostic practices, a trend many countries are only now implementing.
The economic implications of this trend are substantial. Globally, dementia already costs $1.3 trillion annually, and that figure is expected to skyrocket. Critically, Kazakhstan has yet to conduct a national economic assessment of the burden of Alzheimer’s and dementia. This lack of data hinders effective resource allocation and the development of targeted interventions. The absence of a dedicated state program is also a significant concern, with prevention, diagnosis, and treatment currently integrated within the broader healthcare system. While the existing 20 mental health centers are a starting point, they may be insufficient to meet the growing demand.
The Forward Look
The next 12-18 months will be pivotal for Alzheimer’s care in Kazakhstan. The potential introduction of a new blood test capable of identifying early-stage Alzheimer’s – anticipated by the end of 2026 or early 2027 – represents a major opportunity for proactive intervention. However, the true impact will depend on whether this test is widely accessible and integrated into primary healthcare settings. More importantly, the Kazakh healthcare system needs to address the gap in access to newer, disease-modifying treatments like lecanemab and donanemab. Negotiations with pharmaceutical companies and regulatory approvals will be crucial.
Beyond treatment, a fundamental shift in public perception is needed. The ADI’s 2024 report reveals a widespread misconception that dementia is a normal part of aging – a belief held by nearly 80% of the public and a concerning 65% of healthcare professionals. Combating this stigma through public health campaigns and professional training will be essential to encourage early detection and reduce the delayed diagnoses currently observed in Kazakhstan. Finally, the Kazakh Ministry of Health should prioritize a comprehensive economic assessment of dementia’s impact to justify the development of a dedicated national program and secure the necessary funding for long-term care and support services. Without proactive measures, Kazakhstan risks being overwhelmed by the escalating challenges posed by this growing public health crisis.
Discover more from Archyworldys
Subscribe to get the latest posts sent to your email.
